Chinese General Practice ›› 2019, Vol. 22 ›› Issue (9): 1009-1013.DOI: 10.12114/j.issn.1007-9572.2018.00.374
• Monographic Research • Previous Articles Next Articles
Published:
2019-03-20
Online:
2019-03-20
基金资助:
[1]ZELLBER-SAGI S,LOTAN R,SHLOMAI A,et al.Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up[J].J Hepatol,2012,56(5):1145-1151.DOI:10.1016/j.jhep.2011.12.011. [2]YOUNOSSI Z M,KOENIG A B,ABDELAFIF D,et al.Global epidemiology of nonalcoholic fatty liver disease——Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.DOI:10.1002/hep.28431. [3]KANG J H,MATSUI T.Changing etiology in liver cirrhosis in Sapporo,Japan[J].Euroasion J Hepatogastroenterol,2018,8(1):77-80.DOI:10.5005/jp-journals-10018-1266. [4]WU J,XU H,HE X,et al.Six-year changes in the prevalence of obesity and obesity-related diseases in Northeastern China from 2007 to 2013[J].Sci Rep,2017,7:41518.DOI:10.1038/srep41518. [5]CHALASANI N,YOUNOSSI Z,LAVINE J E,et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases,and American College of Gastroenterology[J].Gastroenterology,2012,142(7):1592-1609.DOI:10.1053/j.gastro.2012.04.001. [6]CHALASANI N,YOUNOSSI Z,LAVINE J E,et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology,2018,67(1):328-357.DOI:10.1002/hep.29367. [7]VALLET-PICHARD A,MALLET V,NALPAS B,et al.FIB-4:an inexpensive and accurate marker of fibrosis in HCV infection.comparison with liver biopsy and fibrotest[J].Hepatology,2007,46(1):32-36.DOI:10.1002/hep.21669. [8]KASWALA D H,LAI M,AFDHAL N H.Fibrosis assessment in nonalcoholic fatty liver disease(NAFLD)in 2016[J].Dig Dis Sci,2016,61(5):1356-1364.DOI:10.1007/s10620-016-4079-4. [9]瞬时弹性成像技术(TE)临床应用共识专家委员会.瞬时弹性成像技术(TE)临床应用专家共识(2015年)[J].中国肝脏病杂志(电子版),2015,7(2):12-18.DOI:10.3969/j.issn.1674-7380.2015.02.002. Committee of Experts on the Consensus of Clinical Application of Transient Elastic Imaging(TE).Expert consensus on the clinical application of transient elastic imaging(TE)(2015)[J].Chinese Journal of Liver Diseases(Electronic Version),2015,7(2):12-18.DOI:10.3969/j.issn.1674-7380.2015.02.002. [10]TAPPER E B,CHALLIES T,NASSER I,et al.The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease[J].Am J Gastroenterol,2016,111(5):677-684.DOI:10.1038/ajg.2016.49. [11]Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[M].Geneva:Word Health Organization,2015. [12]BYRNE C D,TARGHER G.NAFLD:a multisystem disease[J]J Hepatol,2015,62(1 Suppl):S47-64.DOI:10.1016/jjhep.2014.12.012. [13]LO L,MCLENNAN S V,WILLIAMS P F,et al.Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis[J].J Hepatol,2011,55(2):435-444.DOI:10.1016/j.jhep.2010.10.039. [14]MUSSO G,GAMBINO R,CASSADER M,et al.Meta-analysis:natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity[J].Ann Med,2011,43(8):617-649.DOI:10.3109/07853890.2010.518623. [15]ANGULO P,HUI J M,MARCHESINI G,et al.The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD[J].Hepatology,2007,45(4):846-854.DOI:10.1002/hep.21496. [16]中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].中华肝脏病杂志,2010,18(3):163-166.DOI:10.3760/cma.j.issn.1007-3418.2010.03.002. The Chinese National Workshop on Fatty Liver and Alcoholic Liver Disease for the Chinese Liver Disease Association.Guidelines for management of nonalcoholic fatty liver disease:an updated and revised edition[J].Chinese Journal of Hepatology,2010,18(3):163-166.DOI:10.3760/cma.j.issn.1007-3418.2010.03.002. [17]中华医学会内分泌学分会.中国2型糖尿病防治指南(2010年版)[J].中国医学前沿杂志(电子版),2011,3(6):54-109. Endocrinology Branch of Chinese Medical Association.Guideline for prevention and treatment of type 2 diabetes in China(2010 Edition)[J].Chinese Journal of the Frontiers of Medical Science(Electronic Version),2011,3(6):54-109. [18]MCPHERSON S,STEWART S F,HENDERSON E,et al.Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease[J].Gut,2010,59(9):1265-1269.DOI:10.1136/gut.2010.216077. [19]SANDRIN L,FOURQUET B,HASQUENOPH J M,et al.Transient elastography:a new noninvasive method for assessment of hepatic fibrosis[J].Ultrasound Med Biol,2003,29(12):1705-1713. [20]中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2010,8(6):324-329. Infectious Diseases and Parasitology Branch of Chinese Medical Association,Liver Disease Branch of Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chinese Journal of Hepatology,2010,8(6):324-329. [21]梁乾飞,王亚东,赵彩彦.河北省居民非酒精性脂肪性肝病的认知调查与分析[J].中华肝脏病杂志,2017,25(10):760-765.DOI:10.3760/cma.j.issn.1007-3418.2017.10.008. LIANG Q F,WANG Y D,ZHAO C Y.Investigation and analysis of the knowledge of nonalcoholic fatty liver disease among residents in Hebei Province,China[J].Chinese Journal of Hepatology,2017,25(10):760-765.DOI:10.3760/cma.j.issn.1007-3418.2017.10.008. [22]严丽波,阎俪,唐红,等.2016年美国肝病研究协会进展报道[J].中华肝脏病杂志,2017,25(2):154-156.DOI:10.3760/cma.j.issn.1007-3418.2017.02.015. YAN L B,YAN L,TANG H,et al.A report of 2016 advances in American Association for the Study of Liver Diseases[J].Chinese Journal of Hepatology,2017,25(2):154-156.DOI:10.3760/cma.j.issn.1007-3418.2017.02.015. [23]YOUNOSSI Z M,LOOMBA R,ANSTEE Q M,et al.Diagnostic modalities for non-alcoholic fatty liver disease,nonalcoholic steatohepatitis,and associated fibrosis[J].Hepatology,2018,68(1):349-360.DOI:10.1002/hep.29721. [24]KIM G A,LEE H C,CHOE J,et al.Association between non-alcoholic fatty liver disease and cancer incidence rate[J].J Hepatol,2018,68(1):140–146.DOI:10.1016/j.jhep.2017.09.012. [25]WANG J,XU C,XUN Y,et al.ZJU index:a novel model for predicting nonalcoholic fatty liver disease in a Chinese population[J].Sci Rep,2015,5:16494.DOI:10.1038/srep16494. [26]KEMP W,LEVY M,WELTMAN M,et al.Australian Liver Association(ALA)expert consensus recommendations for the use of transient elastography in chronic viral hepatitis[J].J Gastroenterol Hepatol,2015,30(3):453-462.DOI:10.1111/jgh.12865. [27]EDDOWES P J,MCDONALD N,DAVIES N,et al.Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2018,47(5):631-644.DOI:10.1111/apt.14469. [28]COLLETTA C,SMIRNE C,FABRIS C,et al.Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases[J].Hepatology,2005,42(4):838-845.DOI:10.1002/hep.20814. [29]WONG V W,VERGNIOL J,WONG G L,et al.Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease[J].Hepatology,2010,51(2):454-462.DOI:10.1002/hep.23312. [30]LOOMBA R,WOLFSON T,ANG B,et al.Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease:a prospective study[J].Hepatology,2014,60(6):1920-1928.DOI:10.1002/hep.27362. |
[1] | LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301. |
[2] | LIN Kai, YAO Mi, CHEN Zhang, JI Xinxin, LIN Runqi, CHEN Yongsong, Sim MOIRA. Conceptual Framework and Responding Approach of Treatment Burden of Type 2 Diabetes: a Video Recording-based Analysis [J]. Chinese General Practice, 2023, 26(34): 4302-4307. |
[3] | YANG Hui, HU Ruwei, LIU Ruqing, LU Junfeng, WU Jinglan. Relationship between Community Health Service Experience and Glycemic Control Outcomes in Patients with Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(34): 4290-4295. |
[4] | ZHANG Juan, LI Haifen, LI Xiaoman, YAO Miao, MA Huizhen, MA Qiang. Construction of Recurrence Risk Prediction Model for Diabetic Foot Ulcer on the Basis of Logistic Regression, Support Vector Machine and BP Neural Network Model [J]. Chinese General Practice, 2023, 26(32): 4013-4019. |
[5] | CHENG Jingwei, QIAO Junjun, YIN Zhen, HU Junpeng, WANG Qinghe, LIU Yangqing, WANG Yanfang. Interpretation of ISPAD Clinical Practice Consensus Guidelines 2022: Exercise in Children and Adolescents with Diabetes [J]. Chinese General Practice, 2023, 26(30): 3719-3724. |
[6] | ZHOU Xiaoqi, LIU Xinhui, ZHANG Wei, LI Changfeng, YAN Yaqiong. Association of Alanine Transaminase and Aspartate Aminotransferase/Alanine Transaminase Ratio with Type 2 Diabetes and Metabolic Syndrome in the Elderly [J]. Chinese General Practice, 2023, 26(29): 3645-3649. |
[7] | ZHAO Xiaohua, DU Lin, GAO Shengnan, JIANG Ziyun. Multiple Deep Muscle Abscesses in Type 2 Diabetes in the Elderly: Report of One Case and Literature Review [J]. Chinese General Practice, 2023, 26(29): 3715-3718. |
[8] | LUO Dan, XU Jingjing, WANG Yubing, LI Mingzi, FORBES Angus. Development and Preliminary Practice of Resilience-oriented Structured Treatment and Educational Program for Adolescents with Type 1 Diabetes [J]. Chinese General Practice, 2023, 26(27): 3423-3429. |
[9] | DONG Yanan, JIANG Xiaorui, WANG Kai, ZONG Chuanchong, LIN Guodong, LI Xiangqing, LIN Chunxiao, CHI Juntao. The Effect of Modified Tibial Transverse Transport Technique in the Treatment of Wagner Grade Ⅲ and Ⅳ Diabetic Foot Patients [J]. Chinese General Practice, 2023, 26(27): 3411-3416. |
[10] | LU Zuowei, CAO Hongwei, LIU Tao, ZHANG Nana, CHEN Yanyan, SHI Qinli, LIU Xiangyang, WANG Qiong, LAI Jingbo, LI Xiaomiao. Development and Validation of a Risk Prediction Model for the Progression from Microalbuminuria to Macroalbuminuria in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(26): 3259-3268. |
[11] | GU Yunjie, SONG Jing, YIN Jun. Clinical Study on Low-carbon Diet for Endogenous-insulin-deficient Diabetes Patients [J]. Chinese General Practice, 2023, 26(26): 3308-3313. |
[12] | KONG Dexian, XING Yuling, SUN Wenwen, ZHANG Zhimin, ZHOU Fei, MA Huijuan. Correlation between Estimated Glucose Disposal Rate and Metabolism-associated Fatty Liver Disease in Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(26): 3252-3258. |
[13] | CHEN Lunwen, ZHOU Yang, YAN Guodong, SHEN Yi, SUN Chen, CAI Wanli, CHU Minjie, XIAO Jing. Risk of Malignant Tumor in Patients with Type 2 Diabetes: a Prospective Population-based Study [J]. Chinese General Practice, 2023, 26(26): 3238-3245. |
[14] | FEI Sijie, ZHANG Qiang, LIU Fangfang, BAI Lu, SUN Caihong, XIN Caifeng. Correlation between Glycated Hemoglobin Variability and New-onset Atrial Fibrillation in Type 2 Diabetes Patients Combined with Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2023, 26(26): 3246-3251. |
[15] | HE Rong, ZHANG Li, LI Peng, ZHANG Xiaoling, ZHANG Guo, ZANG Yiran, WU Shouling, SUN Lixia. Immediate Effects of Aerobic Exercise on Arterial Stiffness in a Male Population with Different Blood Glucose Levels [J]. Chinese General Practice, 2023, 26(24): 2997-3004. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 1297
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 676
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||